Working...
ClinicalTrials.gov
ClinicalTrials.gov Menu

Givinostat in Duchenne's Muscular Dystrophy Long-term Safety and Tolerability Study

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT03373968
Recruitment Status : Recruiting
First Posted : December 14, 2017
Last Update Posted : July 12, 2019
Sponsor:
Collaborator:
Cromsource
Information provided by (Responsible Party):
Italfarmaco

Brief Summary:
This is an open label, long-term safety, tolerability, and efficacy study of GIVINOSTAT in all DMD (Duchenne's muscular dystrophy) patients who have been previously treated in one of the GIVINOSTAT studies.

Condition or disease Intervention/treatment Phase
Duchenne Muscular Dystrophy Drug: Givinostat Phase 2 Phase 3

Detailed Description:

GIVINOSTAT oral suspension (10 mg/mL) has to be administered orally as 2 oral doses daily while the subject is in a fed state. The starting dose of GIVINOSTAT in the present long term study will be the same that the subject was receiving at the end of the previous DMD GIVINOSTAT study.

As weight affects GIVINOSTAT exposures, the dosage will be modified based on subject weight according the rules detailed in the study protocol section 11.2.2.1.

In addition, in case a subject will have a consistent (e.g., at least 2 consecutive evaluations) platelets count ≤150 x 109/L and not meet the stopping criteria for platelets, the Investigator will have to reduce the dose of 1/3 or 20% less of the current dose as described in the study protocol section 10.5.1.3. During the first month of treatment, platelets count assessment will be performed weekly, while during the second month it will be performed every 2 weeks, in order to strictly monitor this parameter for safety reasons, with the exclusion of subjects coming from study DSC/11/2357/43 for which the first visit will be 4 months after the Visit 1/baseline visit.

Study drug should be permanently interrupted if any of the following occurs:

  • severe drug-related diarrhoea (i.e., increase of ≥7 stools per day);
  • any drug-related SAE;
  • QTcF >500 msec;
  • platelets count ≤50 x 109/L;
  • white blood cells ≤2.0 x 109/L;
  • hemoglobin ≤8.0 g/dL; To avoid laboratory errors and anomalous values, test must be confirmed with a repeated test performed on the next working day. The treatment should be stopped until the retest result becomes available. If the repeated test is still under the stopping limit value, study drug must be permanently discontinued. If the repeated test is acceptable, the subject can resume treatment.

The Investigator will follow up the patient until resolution or acceptable stabilization of the event occurs and document all the relevant information, as applicable. After the resolution/stabilization of the event, the subject will be withdrawn from the study and the EOS Visit (see Section 12.1.10) will be performed.

Any decision relevant to the dose adjustment and/or modification of schedule of assessments can be discussed with the Medical Monitor, but the final decision remains with the Investigator only or its authorized designee.


Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 100 participants
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Open Label, Long-term Safety, Tolerability, and Efficacy Study of GIVINOSTAT in All DMD Patients Who Have Been Previously Treated in One of the GIVINOSTAT Studies
Actual Study Start Date : October 24, 2017
Estimated Primary Completion Date : December 2023
Estimated Study Completion Date : December 2023


Arm Intervention/treatment
Experimental: givinostat
Givinostat oral suspension (10 mg/mL) twice daily in a fed state
Drug: Givinostat
suspension of givinostat (10 mg/mL)




Primary Outcome Measures :
  1. Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability] [ Time Frame: Through study completion, an average of 1 year ]
    Type, incidence, and severity of treatment related/not related adverse events(AEs) and serious adverse event (SAEs)



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   7 Years and older   (Child, Adult, Older Adult)
Sexes Eligible for Study:   Male
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Must have participated in one of the previous studies with GIVINOSTAT in DMD and have attended the End of Study Visit;
  • Aged ≥7 years and 6 months old
  • Are able to give informed assent and/or consent in writing signed by the subject and/or parent/legal guardian (according to local regulations);
  • Subjects must be willing to use adequate contraception.

Exclusion Criteria:

  • Use of any pharmacologic treatment, other than corticosteroids, that might have had an effect on muscle strength or function within 3 months prior to be enrolled in this study (e.g., growth hormone); Vitamin D, calcium, and any other supplements will be allowed;
  • Use of any current investigational drug other than Givinostat;
  • Have presence of other clinically significant disease, which, in the Investigator's opinion, could adversely affect the safety of the subject, making it unlikely that the course of treatment or follow-up would be completed, or could impair the assessment of study results;
  • Have a diagnosis of other uncontrolled neurological diseases or presence of relevant uncontrolled somatic disorders that are not related to DMD;
  • Have platelets count, White Blood Cell and Hemoglobin at screening < Lower Limit of Normal (LLN) (for abnormal screening laboratory test results (<LLN), the platelets count, White Blood Cell and Hemoglobin will be repeated once; if the repeat test result is still <LLN, then exclusionary);
  • Have Triglycerides > 300 mg/dL (3.42 mmol/L) in fasting conditionat screening visit (for abnormal screening laboratory test results (>300 mg/dL), the triglycerides will be repeated once;if the repeat test result is still >300 mg/dL , then exclusionary).
  • Have inadequate renal function, as defined by serum Cystatin C >2 x the upper limit of normal (ULN) at screening visit. If the value is >2 x ULN, the serum Cystatin C will be repeated once; if the repeated test result is still >2 x ULN, the subject should be excluded);
  • Have heart failure (New York Heart Association Class III or IV)
  • Have a current liver disease or impairment, including but not limited to an elevated total bilirubin (i.e. > 1.5 x ULN), unless secondary to Gilbert disease or pattern consistent with Gilbert's;
  • Have a baseline QT interval, Fredericia's correction, (QTcF) >450 msec, (as the mean of 3 consecutive readings 5 minutes apart) or history of additional risk factors for torsades de pointes (e.g., heart failure, hypokalemia, or family history of long QT syndrome);
  • Have a psychiatric illness/social situations rendering the potential subject unable to understand and comply with the muscle function tests and/or with the study protocol procedures.
  • Have any hypersensitivity to the components of study medication;
  • Have a sorbitol intolerance or sorbitol malabsorption, or have the hereditary form of fructose intolerance.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03373968


Contacts
Layout table for location contacts
Contact: Reference Study ID Number: DSC/14/2357/51 + 39 02 6443 ext 2524 patientadvocacy@italfarmaco.com

Locations
Layout table for location information
Belgium
University Hospitals Leuven, Neuromuscular Reference Centre, Child Neurology Recruiting
Leuven, Belgium, 03000
Contact: Nathalie Goemans, MD       nathalie.goemans@uzleuven.be   
Principal Investigator: Nathalie Goemans, MD         
Canada, Alberta
Kinsmen Research Centre - Alberta Children's Hospital Recruiting
Calgary, Alberta, Canada, T3B 6A8
Contact: Jean Mah, MD       Jean.Mah@albertahealthservices.ca   
Principal Investigator: Jean Mah, MD         
Italy
A.O.U. Policlinico G. Martino, U.O.C. Neurologia e Malattie Neuromuscolari Recruiting
Messina, Italy, 98125
Contact: Giuseppe Vita, MD       giuseppe.vita@unime.it   
Principal Investigator: Giuseppe Vita, MD         
Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico di Milano, UOS di Neurologia Pediatrica Recruiting
Milan, Italy, 20122
Contact: Giacomo Comi, MD       giacomo.comi@unimi.it   
Principal Investigator: Giacomo Comi, MD         
Ospedale Pediatrico Bambino Gesù, Malattie Neuromuscolari e Neurodegenerative Recruiting
Roma, Italy, 00146
Contact: Enrico Bertini, MD       bertini@opbg.net   
Principal Investigator: Enrico Bertini, MD         
Fondazione Policlinico Universitario "A.Gemelli", UOC Neuropsichiatria Infantile Recruiting
Roma, Italy, 00168
Contact: Eugenio Mercuri, MD       eumercuri@gmail.com   
Principal Investigator: Eugenio Mercuri, MD         
Spain
Neuromuscular Pathology Unit - Hospital Sant Joan de Déu Recruiting
Esplugues De Llobregat, Barcellona, Spain, 08950
Contact: Andres Nascimento, MD       anascimento@sjdhospitalbarcelona.org   
Principal Investigator: Andres Nascimento, MD         
Hospital Materno-Infantil Recruiting
Barcelona, Spain, 08035
Contact: Francina Munell, MD       francina.munell@vhir.org   
Principal Investigator: Francina Munell, MD         
Sponsors and Collaborators
Italfarmaco
Cromsource

Layout table for additonal information
Responsible Party: Italfarmaco
ClinicalTrials.gov Identifier: NCT03373968     History of Changes
Other Study ID Numbers: DSC/14/2357/51
First Posted: December 14, 2017    Key Record Dates
Last Update Posted: July 12, 2019
Last Verified: July 2019
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Undecided

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No

Additional relevant MeSH terms:
Layout table for MeSH terms
Muscular Dystrophies
Muscular Dystrophy, Duchenne
Muscular Disorders, Atrophic
Muscular Diseases
Musculoskeletal Diseases
Neuromuscular Diseases
Nervous System Diseases
Genetic Diseases, Inborn
Genetic Diseases, X-Linked